Skip to main content
. Author manuscript; available in PMC: 2017 Nov 14.
Published in final edited form as: Clin Appl Thromb Hemost. 2016 Sep 16;23(7):755–760. doi: 10.1177/1076029616668405

Table 2. Unadjusted venous thromboembolism incidence rates by clinical characteristics.

VTE/N VTE rate (%) 95% CI p-value

Total 93/943 9.9 8.0,12.0 --

Age§ 0.99* 0.97,1.01 0.41

Gender
Male 66/731 9.0 7.0,11.3 0.09
Female 27/207 13.0 8.8,18.4

Race
Caucasian 83/863 9.6 7.7,11.8 0.38
Other 9/70 12.9 6.1,23.0

Primary tumor location
Bladder 81/777 10.4 8.4,12.8 0.26
Other 11/149 7.4 3.7,12.8

Histology
Urothelial 76/863 8.8 7.0,10.9 <0.001
Non-urothelial 17/80 21.3 12.9,31.8

Primary treated with surgery
Surgery 48/539 8.9 6.6,11.6 0.26
No surgery 45/404 11.1 8.2,14.6

Primary treated with radiation
Radiation 5/48 10.4 3.5,22.7 0.81
No radiation 88/895 9.8 8.0,12.0

CVD or CVD risk factors
Yes 64/496 12.9 10.1,16.2 0.001
No 29/447 6.5 4.4,9.2

Renal dysfunction
Yes 13/77 16.9 9.3,27.1 0.03
No 80/866 9.2 7.4,11.4

COPD
Yes 6/82 7.3 2.7,15.3 0.42
No 87/861 10.1 8.2,12.3

Congestive heart failure
Yes 2/26 7.7 1.0, 25.1 1.00
No 91/917 9.9 8.1,12.0

Khorana risk group
High-risk (≥3) 21/162 13.0 8.2,19.1 0.15
Intermediate-risk (1-2) 72/781 9.2 7.3,11.5

WBC count (WBC/ul)§ 1.00* 0.96,1.05 0.92

Hemoglobin (g/dl)§ 1.01* 0.91,1.13 0.82

Platelet count (plt/ul)§ 1.00* 0.998, 1.001 0.67

Body mass index (kg/m2)§ 1.04* 1.00, 1.08 0.08
§

Calculated as continuous variables

*

Results indicate odds ratios for the given variables